Statistical considerations for a trial of Ebola virus disease therapeutics
Statistical considerations for a trial of Ebola virus disease therapeutics
The 2014 West African outbreak of Ebola virus ravaged Liberia, Sierra Leone, and Guinea, causing hemorrhagic fever and death. The need to identify effective therapeutics was acute. The usual drug development paradigm of phase I, followed by phase II, and then phase III trials would take too long. These and …